In this perspective, we aim to delineate the mechanistic framework of AT1R- and ETAR-targeting agonistic autoantibodies, critically appraise the available clinical evidence, and outline key priorities for their translational validation in cardiovascular disease. This evidence concerns the gene AGTR1 and cardiovascular disorder.